Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -28.18
- Piotroski Score 2.00
- Grade Buy
- Symbol (ONCY)
- Company Oncolytics Biotech Inc.
- Price $1.00
- Changes Percentage (1.53%)
- Change $0.02
- Day Low $0.97
- Day High $1.00
- Year High $1.75
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/15/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.29
- Trailing P/E Ratio -3.62
- Forward P/E Ratio -3.62
- P/E Growth -3.62
- Net Income $-27,752,000
Income Statement
Quarterly
Annual
Latest News of ONCY
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Oncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
The San Antonio breast cancer update presented final results with no further updates at the meeting. The potential for accelerated approval in breast cancer registration study was discussed, aiming fo...
By Yahoo! Finance | 5 days ago
